Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study

JOURNAL OF HEPATOLOGY(2022)

Cited 0|Views16
No score
Key words
glecaprevir/pibrentasvir,cirrhosis,virological response,eight-weeks,hcv-infected,treatment-naive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined